STI-1499

DB16487InvestigationalProtein Based Therapies

STI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.

Mechanism: STI-1499 is a monoclonal antibody being investigated against COVID-19. The antibody is shown to target the SARS-CoV-2 spike protein, binding at the S1 subunit to block the spike protein's interaction with ACE 2 receptors.
Curator reviewed
Code names: STI-1499

Resolves to

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with STI-1499, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.